The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial

The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial

Background: Biologic agents used in patients with inflammatory bowel diseases (IBD) may influence the pathophysiology of coexistent metabolic-dysfunction associated steatotic liver disease (MASLD). This study primarily aimed to evaluate the six-month effect of infliximab or vedolizumab vs. no biolog...

Full description

Bibliographic Details
Main Authors: Apostolis Papaefthymiou, Styliani Sarrou, Konstantinos Pateras, Ilias D. Vachliotis, Georgios Agrotis, Ioanna-Konstantina Sgantzou, Georgios Perifanos, Andreas Kapsoritakis, Matthaios Speletas, Marianna Vlychou, George N. Dalekos, Spyros Potamianos, Antonis Goulas, Jannis Kountouras, Stergios A. Polyzos
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Pharmaceuticals
Subjects:
biologics
inflammatory bowel diseases
metabolic-dysfunction associated steatotic liver disease
metabolic-dysfunction associated steatohepatitis
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
Online Access:https://www.mdpi.com/1424-8247/17/11/1432

Internet

https://www.mdpi.com/1424-8247/17/11/1432

Similar Items